L-carnitine, acetyl-L-carnitine, and pantothenic acid or ubiquinone, combined for prevention and treatment of syndromes related to ineffective energy metabolism
US5973004A · kind A · utility
Inventor
Key dates
| Filing date | Jan 6, 1998 |
| Grant date | Oct 26, 1999 |
| Priority date | — |
| Expiry date | Jan 6, 2018 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K31/22
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A combination can be of L-carnitine and acetyl-L-carnitine, preferably with pantothenic acid or ubiquinone, is administered orally or as a parenteral injection in domesticated animals, especially pet animals, and humans for prevention or treatment of syndromes or diseases arising from dysfunctional energy metabolism. Syndromes involving skeletal and cardiac muscle benefited from L-carnitine, and syndromes related to the central nervous system improved with acetyl-L-carnitine, are effectively treated. The cofactors L-carnitine and acetyl-L-carnitine do not substitute metabolically for each other, and the effects of the combination are found to be synergistic.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.